Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Aims</h3><p>Accumulating studies identified that BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) is integrally involved in the initiation and development of tumors. Nevertheless, the precise biological role and underlying mechanisms of BUB1B in hepatocellular carcinoma (HCC) remain indistinct.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>To figure out the role of BUB1B in HCC, we first assessed its expression using The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) databases. We then verified BUB1B expression in HCC tissues, nontumor tissues, and HCC cell lines through western blotting, quantitative reverse transcription‐polymerase chain reaction, and immunohistochemistry. To explore the specific function of BUB1B in HCC in vivo and in vitro, we performed the flow cytometry, Cell Counting Kit‐8, 5‐ethynyl‐2′‐deoxyuridine incorporation, colony formation, Transwell, wound‐healing, subcutaneous tumor growth, and metastasis assays. Additionally, we identified the BUB1B‐regulated pathways involved in HCC by using gene set enrichment analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Our data displayed that higher BUB1B expression was detected in HCC tissues and HCC cell lines. The overexpression of BUB1B was positively correlated with adverse clinicopathological characteristics. Survival analyses showed that lower recurrence‐free and overall survival rates were correlated with the overexpression of BUB1B in patients with HCC. Moreover, the malignancy of HCC was facilitated by BUB1B both in vivo and in vitro. Lastly, the results were confirmed by western blots, which showed that BUB1B upregulated mTORC1 signaling pathway in HCC. Meanwhile, the oncogenic effect of BUB1B will be impaired when the mTORC1 signaling pathway was inhibited by rapamycin.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>We highlighted that BUB1B played an oncogenic role in HCC and was identified as a possible clinical prognostic factor and a potential novel therapeutic target for HCC.</p></section>

BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways

Integrated Bioinformatics Analysis and Clinical Validation Reveals That High Expression of Mucin 1 in Intrahepatic Cholangiocarcinoma Predicts Recurrence after Curative Resection.

BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway

Overexpressions of Ck2 Beta and Xiap Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

Overexpression of BubR1 Mitotic Checkpoint Protein Predicts Short Survival and Influences the Progression of Cholangiocarcinoma

Apolipoprotein B is Associated with the Microenvironment of Cholangiocarcinoma

Overexpressions of CK2β and XIAP Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

The Predictive Value of BUB1 in the Prognosis of Oral Squamous Cell Carcinoma

Cul4B is a Novel Prognostic Marker in Cholangiocarcinoma

Elucidating the molecular markers and biological pathways associated with extrahepatic cholangiocarcinoma: a transcriptome sequencing study

Bmi1 facilitates the progression of cholangiocarcinoma by inhibiting Foxn2 expression dependent on a histone H2A ubiquitination manner

Exosome-Mediated Bmi1 Promotes Cholangiocarcinoma Growth and Metastasis Through the Differential Regulation of Mir-320B and Mir-27B-3p

BMI1 Promotes Cholangiocarcinoma Progression and Correlates with Antitumor Immunity in an Exosome-Dependent Manner

BUB1 drives the occurrence and development of bladder cancer by mediating the STAT3 signaling pathway

BIRC7 and STC2 Expression Are Associated with Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma

Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype in lung adenocarcinoma

Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer

BAP1 Acts As a Tumor Suppressor in Intrahepatic Cholangiocarcinoma by Modulating the ERK1/2 and JNK/c-Jun Pathways.

Budding uninhibited by benzimidazoles 1 might be a poor prognosis biomarker promoting the progression of papillary thyroid cancer

Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma.

Beclin 1 Deficiency Correlated with Lymph Node Metastasis, Predicts a Distinct Outcome in Intrahepatic and Extrahepatic Cholangiocarcinoma.